Drug Trial Radar · NCT00722371
MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
Last checked: Nov 19, 2026Latest source record: May 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,615
Actual
Start
Sep 5, 2008
Primary completion
Oct 26, 2010
Study completion Mar 25, 2011
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jul 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 78 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate the efficacy and safety of sitagliptin and pioglitazone co-administration in comparison with sitagliptin and pioglitazone monotherapy in patients with type 2 diabetes.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Sitagliptin phosphateDrug
Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
Pioglitazone hydrochlorideDrug
Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
Matching placebo to sitagliptinDrug
Matching placebo to sitagliptin orally once daily for 54 weeks.
Matching placebo to pioglitazoneDrug
Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
MetforminDrug
Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1C (A1C) at Week 24Time frame: Baseline and Week 24
- Change From Baseline in A1C at Week 54Time frame: Baseline and Week 54
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.